company background image
OSX

OsteoporeASX:OSX Stock Report

Market Cap

AU$32.2m

7D

1.9%

1Y

-46.1%

Updated

25 Oct, 2021

Data

Company Financials
OSX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

OSX Overview

Osteopore Limited designs, develops, and markets bioresorbable polymer implants for neurosurgical, orthopedic, and maxillofacial surgery applications.

Osteopore Competitors

Medtronic

NYSE:MDT

US$165.7b

Stryker

NYSE:SYK

US$104.0b

Zimmer Biomet Holdings

NYSE:ZBH

US$31.4b

Price History & Performance

Summary of all time highs, changes and price drops for Osteopore
Historical stock prices
Current Share PriceAU$0.28
52 Week HighAU$0.26
52 Week LowAU$0.65
Beta1.47
1 Month Change-8.33%
3 Month Change-27.63%
1 Year Change-46.08%
3 Year Changen/a
5 Year Changen/a
Change since IPO-62.07%

Recent News & Updates

Shareholder Returns

OSXAU Medical EquipmentAU Market
7D1.9%1.2%0.6%
1Y-46.1%-7.6%21.3%

Return vs Industry: OSX underperformed the Australian Medical Equipment industry which returned -7.6% over the past year.

Return vs Market: OSX underperformed the Australian Market which returned 21.3% over the past year.

Price Volatility

Is OSX's price volatile compared to industry and market?
OSX volatility
OSX Beta1.47
Industry Beta0.57
Market Beta1

Stable Share Price: OSX is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: OSX's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2003n/aKhoon Seng Gohhttps://www.osteopore.com

Osteopore Limited designs, develops, and markets bioresorbable polymer implants for neurosurgical, orthopedic, and maxillofacial surgery applications. It specializes in the production of 3D printed bioresorbable implants that are used in conjunction with surgical procedures to assist with the natural stages of bone healing. The company offers Osteoplug, a bioresorbable implant, which is used for covering trephination burr holes in neurosurgery; Osteomesh, a bioresorbable implant that is used in craniofacial surgery to repair various types of fractures, such as orbital floor fracture, as well as to fill surgical defects; and Osteostrip.

Osteopore Fundamentals Summary

How do Osteopore's earnings and revenue compare to its market cap?
OSX fundamental statistics
Market CapAU$32.25m
Earnings (TTM)-AU$2.63m
Revenue (TTM)AU$1.45m

22.2x

P/S Ratio

-12.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
OSX income statement (TTM)
RevenueAU$1.45m
Cost of RevenueAU$486.34k
Gross ProfitAU$964.80k
ExpensesAU$3.60m
Earnings-AU$2.63m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.022
Gross Margin66.49%
Net Profit Margin-181.43%
Debt/Equity Ratio4.1%

How did OSX perform over the long term?

See historical performance and comparison

Valuation

Is Osteopore undervalued compared to its fair value and its price relative to the market?

4.24x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate OSX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate OSX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: OSX is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.

PE vs Market: OSX is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OSX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OSX is good value based on its PB Ratio (4.2x) compared to the AU Medical Equipment industry average (4.5x).


Future Growth

How is Osteopore forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.2%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Osteopore has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Osteopore performed over the past 5 years?

-25.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OSX is currently unprofitable.

Growing Profit Margin: OSX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OSX is unprofitable, and losses have increased over the past 5 years at a rate of 25% per year.

Accelerating Growth: Unable to compare OSX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OSX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).


Return on Equity

High ROE: OSX has a negative Return on Equity (-34.62%), as it is currently unprofitable.


Financial Health

How is Osteopore's financial position?


Financial Position Analysis

Short Term Liabilities: OSX's short term assets (A$8.2M) exceed its short term liabilities (A$1.1M).

Long Term Liabilities: OSX has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: OSX's debt to equity ratio (4.1%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if OSX's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OSX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: OSX has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 38.3% each year.


Dividend

What is Osteopore current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OSX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OSX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OSX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OSX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OSX's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.1yrs

Average management tenure


CEO

Khoon Seng Goh

2.08yrs

Tenure

AU$216,780

Compensation

Mr. Khoon Seng Goh is the Chief Executive Officer of Osteopore Limited (formerly, Osteopore International Pte. Ltd.) since September 23, 2019 and had been its Director since December 11, 2018 until June 24...


CEO Compensation Analysis

Compensation vs Market: Khoon Seng's total compensation ($USD162.50K) is below average for companies of similar size in the Australian market ($USD302.38K).

Compensation vs Earnings: Khoon Seng's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: OSX's management team is considered experienced (2.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Osteopore Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Osteopore Limited
  • Ticker: OSX
  • Exchange: ASX
  • Founded: 2003
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: AU$32.249m
  • Shares outstanding: 117.27m
  • Website: https://www.osteopore.com

Location

  • Osteopore Limited
  • No. 09-06, 2 Tukang Innovation Grove
  • MedTech Hub
  • Singapore
  • 618305
  • Singapore

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/25 16:54
End of Day Share Price2021/10/25 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.